Telix Pharmaceuticals Limited announces that the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or 'ANVISA') has approve...
AbbVie announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE® (mirvetuximab s...
iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, announced the acquisition of ...
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF&rdq...
Arvinas, Inc. announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulves...
HealthTree Foundation, a global nonprofit dedicated to improving outcomes for blood cancer patients through technology-driven solutions, announces the laun...
Roche announced the launch of the Roche Genentech Innovation Center Boston at Harvard’s Enterprise Research Campus in Allston which will ...
ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies, announced the first patient has been dosed in the co...
Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...
BeiGene, Ltd. a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administr...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...
Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial m...
Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, a...
Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed fundi...
© 2025 Biopharma Boardroom. All Rights Reserved.
